hPSC-CMs

Developed for: heart failure
Investigated by: HELP Therapeutics Co., Ltd. · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

today NCT03763136 · Ph 1/2

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT03763136	Oct 2021 → Apr 2024	heart failure	HELP Therapeutics Co., Ltd.	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	hPSC-CMs	“Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium...” NCT03763136 ↗